


CARDIOLOGY

THE HEART OF THE MATTER





KEY PATENT EXPIRIES BY 2028*

ELIQUIS (BRISTOL MYERS SQUIBB)
2026 - \$9.1 BN AT RISK

TYVASO (UNITED THERAPEUTICS)
2028 - \$2.7 BN AT RISK

ENTRESTO (NOVARTIS)
2027 - \$2.6 BN AT RISK



13 13 19 8
INNOVATIVE MEDTECH APPROVALS*

*(PMAS AND DE NOVO 510(K)S)



TOP PHARMA PLAYERS IN 2028

Bristol Myers Squibb \$9.2 BN

NOVARTIS \$6.1 BN

United Therapeutics \$4 BN



TOP MEDTECH PLAYERS IN 2028

Medtronic \$12.9 BN

Abbott \$12.1 BN

Boston Scientific \$11 BN




MARKET SIZE BIOPHARMA

+ 0.5% CAGR 2021-2028
\$61.7 BN WW SALES IN 2028



MARKET SIZE MEDTECH

+6% CAGR 2021
\$86.3 BN IN 2028



*Sales at risk refers to a product's annual revenue in the year before loss of exclusivity.

Evaluate

a norstella company